Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 9,364 matching trials from the live ClinicalTrials.gov search.
Filters: Portland, Oregon Clear all
Completed No phase listed Observational

Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors

NCT00919750
View directory record Official record
Conditions
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Cerebral Anaplastic Astrocytoma, Childhood Cerebral Astrocytoma, Childhood Choroid Plexus Neoplasm, Childhood Craniopharyngioma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood Infratentorial Ependymoma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Ependymoma, Newly Diagnosed Childhood Ependymoma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Supratentorial Embryonal Tumor, Not Otherwise Specified, Recurrent Childhood Visual Pathway Glioma
Interventions
Cytology Specimen Collection Procedure
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 18 Years
Enrollment
1,258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
163
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 123 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Nov 5, 2026, 4:05 PM EST
Completed Phase 2 Interventional Results available

ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease

NCT00934050
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ELND005 (scyllo-inositol)
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
Not listed
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
30
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Nov 5, 2026, 4:05 PM EST
Recruiting Phase 3 Interventional

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

NCT05677490
View directory record Official record
Conditions
Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
Interventions
Fluorouracil, Leucovorin Calcium, Oxaliplatin, Irinotecan, Nivolumab, Magnetic Resonance Imaging, Computed Tomography, Biospecimen Collection, Questionnaire Administration
Drug · Biological · Procedure + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
795
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 510 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 5, 2026, 4:05 PM EST
Recruiting Phase 2 Interventional

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

NCT05040360
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor, Stage I Pancreatic Neuroendocrine Tumor AJCC v8, Stage II Pancreatic Neuroendocrine Tumor AJCC v8, Stage III Pancreatic Neuroendocrine Tumor AJCC v8
Interventions
Capecitabine, Temozolomide
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
446
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 300 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Nov 5, 2026, 4:05 PM EST
Active, not recruiting Phase 3 Interventional

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

NCT04498117
View directory record Official record
Conditions
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
Interventions
Oregovomab, Paclitaxel, Carboplatin, Placebo
Biological · Drug
Lead sponsor
CanariaBio Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
81
States / cities
Phoenix, Arizona • Tucson, Arizona • Concord, California + 70 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Nov 5, 2026, 4:05 PM EST
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention

NCT02456740
View directory record Official record
Conditions
Migraine
Interventions
Erenumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
955 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
59
States / cities
Phoenix, Arizona • Anaheim, California • Encino, California + 55 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Nov 5, 2026, 4:05 PM EST
Completed Phase 3 Interventional Results available

First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks

NCT01555125
View directory record Official record
Conditions
Moderate to Severe Plaque-type Psoriasis
Interventions
secukinumab 150 mg, secukinumab 300 mg, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
18
States / cities
Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Nov 5, 2026, 4:05 PM EST
Completed No phase listed Observational Accepts healthy volunteers

DPBRN Reasons for Replacement or Repair of Dental Restorations

NCT01201876
View directory record Official record
Conditions
Dental Caries
Interventions
Not listed
Lead sponsor
Dental Practice-Based Research Network
Network
Eligibility
6 Years and older
Enrollment
6,368 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
6
States / cities
Birmingham, Alabama • Gainesville, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Nov 5, 2026, 4:05 PM EST
Completed Not applicable Interventional Results available

GET FIT Prostate: A Randomized Controlled Exercise Trial

NCT03741335
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Resistance Training, Stretching, Tai Chi
Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Nov 5, 2026, 4:05 PM EST
Completed Phase 3 Interventional

Effectiveness Study of Vilazodone to Treat Depression and to Discover Genetic Markers Associated With Response

NCT00285376
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
vilazodone
Drug
Lead sponsor
Genaissance Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
15
States / cities
Los Alamitos, California • Newport Beach, California • Northridge, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2008 · Synced Nov 5, 2026, 4:05 PM EST
Not listed No phase listed Observational

Post-Market Clinical Investigation of the IotaSOFT Insertion System

NCT06664697
View directory record Official record
Conditions
Hearing Loss, Cochlear, Cochlear Implantation, Hearing Loss, Sensorineural
Interventions
Cochlear Implantation with Robotic-Assisted Insertion System
Device
Lead sponsor
iotaMotion, Inc.
Industry
Eligibility
12 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Indianapolis, Indiana • Iowa City, Iowa • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Nov 5, 2026, 4:05 PM EST
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease

NCT04592874
View directory record Official record
Conditions
Alzheimer Disease
Interventions
AL002, Placebo
Drug
Lead sponsor
Alector Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
29
States / cities
Phoenix, Arizona • Rogers, Arkansas • Costa Mesa, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Nov 5, 2026, 4:05 PM EST
Terminated Phase 2 Interventional Results available

Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects

NCT00709618
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Lapatinib, Vinorelbine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
22
States / cities
Muscle Shoals, Alabama • Tucson, Arizona • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Nov 5, 2026, 4:05 PM EST
Completed Phase 4 Interventional

The Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)

NCT00293176
View directory record Official record
Conditions
Memory Loss
Interventions
Donepezil Hydrochloride, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
45 Years to 90 Years
Enrollment
821 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
54
States / cities
Albaster, Alabama • Mesa, Arizona • Peoria, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2011 · Synced Nov 5, 2026, 4:05 PM EST
Completed Phase 3 Interventional Results available

Age-Related Eye Disease Study 2 (AREDS2)

NCT00345176
View directory record Official record
Conditions
Age-related Macular Degeneration, Cataract
Interventions
Lutein/zeaxanthin, DHA/EPA, Lutein/zeaxanthin and DHA/EPA
Dietary Supplement · Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years to 85 Years
Enrollment
4,203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
91
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 72 more
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Nov 5, 2026, 4:05 PM EST
Recruiting Phase 2 Interventional Results available

A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

NCT04710576
View directory record Official record
Conditions
Chronic Graft-versus-host-disease
Interventions
Axatilimab
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
47
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Nov 5, 2026, 4:05 PM EST
Completed Phase 2 Interventional Results available

Study of Safety & Tolerability of OPC-34712 as Adjunctive Therapy in Treatment of Adult Patients With Major Depressive Disorder

NCT01447576
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ADT, OPC-34712
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,036 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
32
States / cities
Arcadia, California • San Diego, California • Sherman Oaks, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2015 · Synced Nov 5, 2026, 4:05 PM EST
Active, not recruiting Not applicable Interventional

Examining the Effectiveness of Asynchronous Versus Synchronous Yoga for Veterans With Chronic Pain

NCT06973876
View directory record Official record
Conditions
Chronic Pain, Yoga
Interventions
Pain-Sensitive Teleyoga Primer, Synchronous Teleyoga, Asynchronous Teleyoga
Behavioral
Lead sponsor
Portland VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Nov 5, 2026, 4:05 PM EST
Completed No phase listed Observational

Neurobehavioral Complications in Children Who Were Previously Treated With Steroids and Intrathecal Therapy for Acute Lymphoblastic Leukemia

NCT00085176
View directory record Official record
Conditions
Leukemia, Long-term Effects Secondary to Cancer Therapy in Children, Neurotoxicity, Psychosocial Effects of Cancer and Its Treatment
Interventions
management of therapy complications, psychosocial assessment and care
Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
6 Years to 16 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
31
States / cities
Phoenix, Arizona • Loma Linda, California • Long Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2014 · Synced Nov 5, 2026, 4:05 PM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease

NCT02180217
View directory record Official record
Conditions
Cushings Disease
Interventions
osilodrostat, LCI699 matching placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
12
States / cities
Aurora, Colorado • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Nov 5, 2026, 4:05 PM EST
Recruiting No phase listed Observational

Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts

NCT06271291
View directory record Official record
Conditions
Pancreatic Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
11
States / cities
Scottsdale, Arizona • San Francisco, California • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Nov 5, 2026, 4:05 PM EST
Completed Phase 1 Interventional

A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)

NCT04196491
View directory record Official record
Conditions
Multiple Myeloma
Interventions
bb2121, Fludarabine, Cyclophosphamide, Lenalidomide
Biological · Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Nov 5, 2026, 4:05 PM EST
Completed Phase 3 Interventional Results available

Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema

NCT01627249
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
2.0 mg intravitreal aflibercept, 1.25 mg intravitreal bevacizumab, 0.3 mg intravitreal ranibizumab
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
90
States / cities
Tucson, Arizona • Beverly Hills, California • Loma Linda, California + 72 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Nov 5, 2026, 4:05 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy Volunteers

NCT02932904
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Vortioxetine, Paroxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 40 Years
Enrollment
361 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
15
States / cities
Encino, California • Long Beach, California • Torrance, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2018 · Synced Nov 5, 2026, 4:05 PM EST